Levosimendán Altan

Levosimendan, the active ingredient in Levosimendán Altan, is a calcium sensitizer presented as an intravenous solution for intravenous administration. It is indicated for the treatment of acute decompensated heart failure, providing inotropic support and vasodilation in hospitalized patients with severe cardiac dysfunction.

GNH USA supplies Levosimendán Altan as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, delivering the product to hospitals, transplant centres and specialty clinics worldwide while ensuring consistent quality and regulatory compliance.

Levosimendan is used in the management of acute decompensated heart failure, a condition characterized by sudden worsening of cardiac function. - Acute decompensated heart failure: improves cardiac output, reduces pulmonary congestion, and alleviates symptoms of low cardiac output in hospitalized patients.

Levosimendan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypotension: drop in blood pressure, especially after infusion start. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Dizziness: feeling light‑headed or unsteady. - Tachycardia: increased heart rate. - Flushing: warm sensation and reddening of skin.

Serious or Rare Side Effects: - Severe hypotension: potentially requiring vasopressor support. - Ventricular arrhythmias: life‑threatening heart rhythm disturbances. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Allergic reactions: rash, pruritus, or anaphylaxis. - Pulmonary edema worsening: fluid accumulation in lungs. - Liver enzyme elevation: abnormal hepatic function tests.

Levosimendan requires careful clinical monitoring and specific handling precautions. - Blood pressure monitoring: observe for hypotension during and after infusion. - Cardiac rhythm surveillance: watch for arrhythmias, especially in patients with existing conduction disorders. - Renal function assessment: adjust use in severe renal impairment. - Hepatic function assessment: caution in patients with significant liver disease. - Concomitant vasodilator use: avoid simultaneous high‑dose nitrates or other vasodilators. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase levosimendan exposure. - Other calcium sensitizers: additive inotropic effect can cause excessive cardiac stimulation. - Potent vasodilators (e.g., high‑dose nitroglycerin): risk of severe hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive effects. - Beta‑blockers: may blunt desired inotropic response. - ACE inhibitors or ARBs: monitor blood pressure and renal function. - Nitrates at standard doses: watch for additive vasodilation. - Other inotropes (e.g., dobutamine): assess for synergistic cardiac effects.